跳转至内容
Merck
CN
所有图片(3)

文件

480789

Sigma-Aldrich

次水杨酸铋(III)

99.9% trace metals basis

登录查看公司和协议定价
所有图片(3)
别名:
次水杨酸铋, 水杨酸铋, 水杨酸铋(III) 碱性
线性分子式:
HOC6H4COOBiO
CAS号:
14882-18-9
分子量:
362.09
EC 号:
238-953-1
MDL编号:
MFCD00085368
UNSPSC代码:
12352300
PubChem化学物质编号:
24871718
NACRES:
NA.22

质量水平

100

检测方案

99.9% trace metals basis

反应适用性

core: bismuth
reagent type: catalyst

mp

>350 °C (lit.)

SMILES字符串

O[Bi]1OC(=O)c2ccccc2O1

InChI

1S/C7H6O3.Bi.H2O/c8-6-4-2-1-3-5(6)7(9)10;;/h1-4,8H,(H,9,10);;1H2/q;+3;/p-3

InChI key

ZREIPSZUJIFJNP-UHFFFAOYSA-K

相关类别

一般描述

铋（III）次水杨酸盐（BSS）主要用于基于铋的药物，以治疗胃肠道疾病 和腹泻。

应用

  • Use of ferric chloride to identify salicylate-containing poisons.: This study explores the use of ferric chloride to detect salicylate compounds, including Bismuth subsalicylate, highlighting its significance in toxicological screenings and emergency treatments. (Hoffman RJ et al., 2002).
  • Effect of pepper and bismuth subsalicylate on gastric pain and surface hydrophobicity in the rat.: Investigates the effects of Bismuth subsalicylate on gastric pain and stomach lining properties, providing insights into its gastroprotective mechanisms. (Lichtenberger LM et al., 1998).
  • The coccoid forms of Helicobacter pylori. Criteria for their viability.: Examines the effectiveness of Bismuth subsalicylate in targeting different morphological forms of Helicobacter pylori, contributing to its role in eradication therapies. (Bode G et al., 1993).
  • Bismuth therapy in gastrointestinal diseases.: A comprehensive review of the therapeutic applications of Bismuth subsalicylate in treating various gastrointestinal disorders, underscoring its pharmacological benefits and safety profile. (Gorbach SL, 1990).

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

D W Bierer
Reviews of infectious diseases, 12 Suppl 1, S3-S8 (1990-01-01)
Pepto-Bismol, which contains bismuth subsalicylate (BSS) as the active ingredient, has been marketed in the United States for more than 80 years. In the gastrointestinal tract, BSS is converted to salicylic acid and insoluble bismuth salts. The salicylate portion of
Rhoswen Lloyd et al.
Nursing standard (Royal College of Nursing (Great Britain) : 1987), 26(40), 51-56 (2012-08-02)
This article describes the prevention and treatment of travellers' diarrhoea, the leading cause of illness in people travelling abroad. The most common cause of travellers' diarrhoea worldwide is bacterial pathogens, which account for up to 80% of cases. Exercising caution
N Chande et al.
The Cochrane database of systematic reviews, (2)(2), CD006096-CD006096 (2008-04-22)
Lymphocytic colitis is a cause of chronic diarrhea. Therapy is based mainly on case series and uncontrolled trials, or by extrapolation of data for treating collagenous colitis, a related disorder. This review was performed to identify therapies for lymphocytic colitis
Copolymerizations of e-Caprolactone and Glycolide A Comparison of Tin (II) Octanoate and Bismuth (III) Subsalicylate as Initiators.
Kricheldorf HR and Rost S.
Biomolecules, 6(3), 1345-1352 (2005)
M D Manhart
Reviews of infectious diseases, 12 Suppl 1, S11-S15 (1990-01-01)
This report demonstrates that bismuth subsalicylate (BSS) effectively inhibits growth of a number of bacterial strains known to cause diarrhea, including Escherichia coli, Salmonella, Shigella, and Campylobacter. Other bismuth salts and sodium salicylate, a hydrolysis product of BSS in the
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门